AI-Driven Discovery Portfolio
Inflammatory Diseases, Cancer, Heart Failure, other unmet needs
DiscoveryActive
Key Facts
Indication
Inflammatory Diseases, Cancer, Heart Failure, other unmet needs
Phase
Discovery
Status
Active
Company
About AgnistaBio
AgnistaBio is an early-stage, private AI-driven biotechnology company leveraging its proprietary AgnistaAI platform (comprising AgTa-Pro, AgTa-Ab, and AgTa-cPep modules) to revolutionize drug discovery. The platform aims to predict dynamic, 4D protein-protein interactomes and design developable human antibodies and cyclic peptides against challenging targets like GPCRs and cryptic epitopes. The company is pre-revenue and operates a platform/therapeutics hybrid business model, seeking partnerships and co-development deals with pharmaceutical and biotech firms to advance its pipeline.
View full company profile